<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064761</url>
  </required_header>
  <id_info>
    <org_study_id>43CASA2006</org_study_id>
    <nct_id>NCT05064761</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite</brief_title>
  <official_title>A Pilot Study to Evaluate Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study has been designed to evaluate the safety and effectiveness of PLLA as a&#xD;
      single regimen for the improvement in appearance of cellulite after changes in reconstitution&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cellulite is a topographic and localized skin condition that is commonly found on the&#xD;
      posterolateral thighs, buttocks, and abdomen. It is often identified by a dimpled or&#xD;
      orange-peel appearance of the skin's surface. The presence of visible cellulite is associated&#xD;
      with histologic changes in the dermis, adipose tissue, and septae.&#xD;
&#xD;
      Based on the theory that a stronger skin structure, with a decrease in skin laxity and&#xD;
      increase in dermal thickness, could reduce the appearance of cellulite, the Sponsor intends&#xD;
      to investigate the safety and effectiveness of PLLA for the improvement in appearance of&#xD;
      cellulite in the posterior thighs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate GAIS</measure>
    <time_frame>Month 9</time_frame>
    <description>Percentage of responders, defined as having at least &quot;Improved&quot; on both thighs according to the Global Aesthetic Improvement Scale (GAIS), as assessed live by the Treating Investigator.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLLA new dilution for treatment to improve appearance of cellulite.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sculptra new dilution</intervention_name>
    <description>Treatment to improve appearance of cellulite.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with intent to undergo treatment to improve appearance of cellulite in the&#xD;
             posterior thighs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known/previous allergy or hypersensitivity to any of the Sculptra constituents.&#xD;
&#xD;
          -  Known/previous allergy or hypersensitivity to lidocaine and other local anesthetics,&#xD;
             e.g. amide-type anesthetics, or topical anesthetics or nerve blocking agents.&#xD;
&#xD;
          -  Previous or present multiple allergies or severe allergies, such as manifested by&#xD;
             anaphylaxis or angioedema, or family history of these conditions.&#xD;
&#xD;
          -  Previous treatment/procedure in or near the treatment area:&#xD;
&#xD;
               1. Previous permanent implant, filler, lifting threads, or autologous fat in the&#xD;
                  treatment area, regardless of time.&#xD;
&#xD;
               2. Previous semi-permanent implants exemplified by Calcium Hydroxylapatite (CaHA),&#xD;
                  poly l-lactic acid (PLLA) in treatment area, regardless of time.&#xD;
&#xD;
               3. Previous Hyaluronic acid (HA) filler or collagen filler in the treatment area&#xD;
                  within 12 months.&#xD;
&#xD;
               4. Previous energy based aesthetic procedures (e.g. laser, intense pulsed light,&#xD;
                  radiofrequency and endermology) in the treatment area within 6 months.&#xD;
&#xD;
               5. Previous mechanical (e.g. dermabrasion, needling) or chemical aesthetic&#xD;
                  procedures (e.g. chemical peel) in the treatment area within 6 months.&#xD;
&#xD;
               6. Previous treatment with cryotherapy, lipolytic treatments or liporeduction&#xD;
                  massage in the treatment area within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Q-Med AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>+1 817-961-5000</phone>
    <email>aestheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Humphrey</last_name>
    </contact>
    <investigator>
      <last_name>Shannon Humphrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

